How do you incorporate post-inflammatory pigmentary metrics (like the PCDA-Derm scale) into your therapeutic selection between IL-13 monotherapy, IL-4/13 dual blockade, and JAK inhibitors specifically when treating moderate-to-severe atopic dermatitis in patients with Fitzpatrick IV-VI skin?